Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.1K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

433
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
433

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reverse engineering of motor unit discharge in multiple sclerosis reveals heterogeneity of voluntary motor commands.

medRxiv : the preprint server for health sciences·2026
Same author

A novel methodological framework for the assessment of the neural control of the shoulder using high-density surface electromyography.

Methods (San Diego, Calif.)·2026
Same author

The increase in time to task failure following endurance training is associated with adjustments in motor unit firing properties.

Journal of applied physiology (Bethesda, Md. : 1985)·2026
Same author

Effect of intensive care unit hospitalization for acute respiratory distress syndrome on strength, fatigue and motor unit behaviour.

Scientific reports·2026
Same author

Differential changes in the effective neural drive following new motor skill acquisition between vastus lateralis and medialis.

European journal of applied physiology·2026
Same author

Implementing sustainable liver health in Europe: a second EASL-Lancet Commission.

Lancet (London, England)·2026

Related Experiment Video

Updated: Feb 27, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

[Is there hope for hepatitis delta ?]

Stefano Guglielmi1, Jean-Louis Frossard2, Francesco Negro3

  • 1Service de médecine interne générale, HUG, 1211 Genève 14.

Revue Medicale Suisse
|July 5, 2017
PubMed
Summary
This summary is machine-generated.

Hepatitis D virus (HDV) infection is a severe liver disease. New therapies targeting HDV

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Area of Science:

  • Hepatology and Virology

Background:

  • Hepatitis D virus (HDV) causes severe chronic liver disease, affecting 15-20 million people globally.
  • HDV infection requires the hepatitis B virus (HBV) for replication, making it a severe form of viral hepatitis.
  • Current treatments like pegylated interferon alpha achieve viral eradication in only 25% of patients.

Purpose of the Study:

  • To explore novel therapeutic strategies for Hepatitis D infection.
  • To identify new treatments that target the Hepatitis D virus life cycle.
  • To address the unmet medical need for effective Hepatitis D management.

Main Methods:

  • Review of emerging therapeutic agents targeting HDV.
  • Analysis of drugs inhibiting HDV entry (e.g., Myrcludex-B).
  • Evaluation of compounds affecting viral assembly (e.g., lonafarnib) and release (e.g., REP 2139).

Main Results:

  • Myrcludex-B demonstrates potential by inhibiting HDV entry into hepatocytes.
  • Lonafarnib offers a mechanism to prevent viral particle assembly.
  • REP 2139 shows promise in impeding viral exit, though mechanisms require further elucidation.

Conclusions:

  • Emerging therapies targeting specific stages of the HDV life cycle show promise.
  • New treatments like Myrcludex-B, lonafarnib, and REP 2139 offer potential for improved Hepatitis D management.
  • Further research is needed to establish the efficacy and safety of these novel therapeutic approaches for chronic Hepatitis D.